Q-omics provides the consensus-scored RRP8 profile across patient tissues and cancer cell-line models. RRP8 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RRP8 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, RRP8 protein abundance shows 33,066 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, KIRC, and GBM as cancer lineages where RRP8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RRP8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RRP8 survival associations across molecular data types. RRP8 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (3) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RRP8 RNA expression–survival associations across cancer types. High RRP8 expression shows unfavorable associations in ACC, LIHC, KICH, KIRC, LGG and MESO. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RRP8 RNA expression.
This table summarizes RRP8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 13. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RRP8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RRP8 shows higher tumor expression in KIRC, LIHC, HNSC, COAD, CHOL and KIRP. The KIRC box plot shows higher RRP8 RNA expression in tumor versus normal tissue (log2 FC = +0.352, t-test p < 0.001).
This table shows molecular features associated with RRP8 in patient tissues and cancer cell lines. In patient samples, RRP8 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RRP8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
